Armune BioScience, in partnership with the University of Michigan, has developed a new technology that measures specific biological markers known to be associated with an immune system response to cancer.
Now available for commercial use, APIFINY® is our proprietary, patented technology that may aid clinicians in the assessment of risk for the presence of prostate cancer.
- APIFINY measures eight autoantibodies released by the immune system in response to the presence of prostate cancer.
- APIFINY autoantibodies were discovered by research conducted at the University of Michigan under the direction of Arul Chinnaiyan, MD, PhD.
- APIFINY does not rely on PSA or a calculation based on various forms of PSA.
How Apifiny Works
- Sample collection and packaging materials are sent upon request with APIFINY Test Requisition Forms, Prepaid FedEx Domestic Airbill, and Clinical Paks.
- Blood is collected from patient using either a normal blood-draw procedure or quick finger-stick.
- The sample is shipped via overnight delivery to Armune’s high-complexity CLIA laboratory.
- Blood is assayed and an APIFINY Prostate Cancer Risk Assessment Score is assigned.
- The results report is sent to the ordering physician.
- The physician interprets the APIFINY Score combined with existing patient information and discusses the next potential steps in the healthcare process with the patient.
Ongoing research based on Armune’s proprietary serum technology is focused on developing:
- Improvements in the early detection of cancer to improve survival rates.
- Monitoring tools on cancer progression from indolent to aggressive disease.
- Risk-assessment tools for lung and breast cancers. In the U.S., lung cancer is the leading cause of cancer deaths. Breast cancer is the most commonly diagnosed cancer in U.S. women, and, after lung cancer, is the second leading cause of cancer deaths in women.
- Enhanced tools to identify appropriate patients for immunotherapy and monitor cancer therapeutic effectiveness.